These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34940082)

  • 41. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
    Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
    Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience.
    Bastard P; Cozic N; Brion R; Gaspar N; Piperno-Neumann S; Cordero C; Leculée-Thébaud E; Gomez-Mascard A; Rédini F; Marchais A; Ikonomova R; Cleirec M; Laurence V; Rigaud C; Abbas R; Verrecchia F; Brugières L; Minard-Colin V
    Pediatr Blood Cancer; 2024 Jul; 71(7):e31029. PubMed ID: 38679845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
    Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
    J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas.
    Wang B; Yao H; Xie X; Yin J; Zou C; Huang G; Shen J
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):221-227. PubMed ID: 29808416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histologic Response and Toxicity following Interval-Compressed Four-Drug Therapy Given Preoperatively in Children and Young Adults with Osteosarcoma: A Retrospective Study.
    Kang JM; Ju HY; Joo J; Sung JY; Park SY; Kim JH; Kang HG; Kwon M; Park M; Park HJ; Park BK
    Oncology; 2020; 98(2):81-90. PubMed ID: 31509843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
    Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
    J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
    Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
    Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
    Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
    Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.
    Erdoğan F; Çinka H; Akman BÇ; Coşkun HS; Dabak N
    Jt Dis Relat Surg; 2023; 34(1):196-206. PubMed ID: 36700283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
    Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
    J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes and survival rates of childhood osteosarcoma in Iran, A report from MAHAK Pediatric Cancer Treatment and Research Center, from 2007 to 2020.
    Mehrvar A; Mehrvar N; Sadeghi Y; Tashvighi M
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S272-S277. PubMed ID: 37148004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
    Hawkins DS; Arndt CA
    Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.
    Bajpai J; Chandrasekharan A; Simha V; Talreja V; Karpe A; Pandey N; Singh A; Rekhi B; Vora T; Ghosh J; Banavali S; Gupta S
    J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
    Tabone MD; Kalifa C; Rodary C; Raquin M; Valteau-Couanet D; Lemerle J
    J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation between apparent diffusion coefficient and histopathology subtypes of osteosarcoma after neoadjuvant chemotherapy.
    Wang J; Sun M; Liu D; Hu X; Pui MH; Meng Q; Gao Z
    Acta Radiol; 2017 Aug; 58(8):971-976. PubMed ID: 27852643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
    Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
    J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
    Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
    Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
    Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
    Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.
    Marec-Berard P; Laurence V; Occean BV; Ray-Coquard I; Linassier C; Corradini N; Collard O; Chaigneau L; Cupissol D; Kerbrat P; Saada-Bouzid E; Delcambre C; Gouin F; Guillemet C; Jimenez M; Lervat C; Gaspar N; Le Deley MC; Brugieres L; Piperno-Neumann S
    J Adolesc Young Adult Oncol; 2020 Apr; 9(2):172-182. PubMed ID: 31702419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.